Ivax paclitaxel
Executive Summary
Company expects to ship $30 mil. of the anticancer agent by the end of the year. Shipment of the generic version of Bristol's Taxol, which began Oct. 23, was delayed due to litigation by Bristol-Myers Squibb and American BioSciences (1"The Pink Sheet" Aug. 28, p. 8). Ivax' ANDA was approved Sept. 15
You may also be interested in...
Bristol/ABI Paclitaxel Settlement Awaits Sept. 6 Hearing; Ivax To Appear
Bristol-Myers Squibb and American BioSciences, Inc. have agreed to a consent order requiring Bristol to continue to list an ABI paclitaxel patent in FDA's "Orange Book."
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials